Triphosphate

Triphosphate

SCHEMBL4816450

O=P(O)(O)OP(=O)(O)OP(=O)(O)O.O=c1[nH]cc(F)c(=O)[nH]1

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TYMS

The experimentally established mechanism targets of Triphosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.63
▸ ALDH1A1 P00352 3/20 0.63
▸ MAPT P10636 2/20 0.63
▸ CYP19A1 P11511 1/20 0.63
▸ TSHR P16473 1/20 0.63
▸ THPO P40225 1/20 0.63
▸ MTOR P42345 1/20 0.63
▸ HTT P42858 1/20 0.63
▸ HBB P68871 1/20 0.63
▸ PMP22 Q01453 1/20 0.63
▸ SMN1; SMN2 Q16637 1/20 0.63
▸ GAA P10253 2/20 0.40
▸ DPYD Q12882 4/20 0.36
▸ ATAD2 Q6PL18 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluorouracil SCHEMBL2445480 0.86 LMNA (0.79) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL869855 0.86 LMNA (0.79) LMNAALDH1A1MAPTCYP19A1TSHR
Triphosphate SCHEMBL1452489 0.80 ATAD2 (0.63) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL10017187 0.80 — —
Fluorouracil SCHEMBL249289 0.80 MAPT (1.00) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL21880166 0.78 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL7650203 0.78 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL21527805 0.78 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL15284932 0.78 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR
Fluorouracil SCHEMBL31441196 0.78 MAPT (0.95) LMNAALDH1A1MAPTCYP19A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117586331-A Key intermediate of 5-fluorouracil deoxynucleoside triphosphate and preparation method thereof 精华制药集团南通有限公司 2024-02-23 — — CN claimed
CN-118221754-A 5-Fluorouracil deoxynucleoside triphosphate intermediate and preparation method thereof 精华制药集团南通有限公司 2024-06-21 — — CN disclosed
CN-118165058-A Intermediate 5-fluoro-3 ' -O-acetyl-5 ' -O-tert-butyl dimethyl silicon-2 ' -deoxyuridine and preparation method thereof 精华制药集团南通有限公司 2024-06-11 — — CN disclosed
CN-117586331-A Key intermediate of 5-fluorouracil deoxynucleoside triphosphate and preparation method thereof 精华制药集团南通有限公司 2024-02-23 — — CN disclosed
CN-114891761-B Tth DNA polymerase mutant and application thereof 上海威高医疗技术发展有限公司 2024-01-12 — — CN disclosed
CN-109562170-B anti-CD 98 antibodies and antibody drug conjugates 艾伯维公司(US) 2023-01-13 — — CN disclosed
CN-114891761-A Tth DNA polymerase mutant and application thereof 上海威高医疗技术发展有限公司 2022-08-12 — — CN disclosed
US-20220202902-A1 COMPOSITIONS COMPRISING A TWEAK LIGAND AND METHODS OF USING SAME CHILDREN'S HOSPITAL MEDICAL CENTER 2022-06-30 — — US disclosed
EP-3962532-A1 COMPOSITIONS COMPRISING A TWEAK LIGAND AND METHODS OF USING SAME Children's Hospital Medical Center (US) 2022-03-09 — — EP disclosed
CN-112245548-A Medicine for treating gastric cancer by combining traditional Chinese medicine and western medicine 梅钊 2021-01-22 — — CN disclosed
WO-2020223302-A1 COMPOSITIONS COMPRISING A TWEAK LIGAND AND METHODS OF USING SAME CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2020-11-05 — — WO disclosed
WO-2008134044-A2 VIRAL VECTOR DRIVEN MUTANT BACTERIAL CYTOSINE DEAMINASE GENE AND USES THEREOF BUCHSBAUM DONALD J (US) 2008-11-06 — — WO disclosed
US-20070225245-A1 Viral vector driven mutant bacterial cytosine deaminase gene and uses thereof BUCHSBAUM DONALD J 2007-09-27 — — US disclosed
Send feedback